Edgewise (EWTX) stock gains on upbeat interim results from the ARCH study of its lead candidate EDG-5506 in adults with Becker Muscular Dystrophy (BMD).
Company Announcement No. 34 / 2022 Interim report for H1 2022 Zealand Pharma Announces Financial Results for the First Half of 2022 Copenhagen, DK...
NOTICE TO HOLDERS OF AMERICAN DEPOSITARY SHARES (“ADSs”)EVIDENCED BYAMERICAN DEPOSITARY RECEIPTS (“ADRs”)REPRESENTING DEPOSITED ORDINARY SHARES...
Company announcement – No. 32 / 2022 Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the U.S.-Based Nasdaq Global Select...
Company announcement – No. 31 / 2022 Zealand Pharma Hosts Conference Call on August 11 at 4 pm CET (10am ET) to Present Second Quarter Results for...
Zealand Pharma AS (ZEAL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down...
Company announcement – No. 30 / 2022 Total number of shares and voting rights in Zealand Pharma at June 30, 2022 Copenhagen, DK and Boston, MA, June 30,...
Iktos, a company specialized in Artificial Intelligence for new drug design, today announced a research collaboration with Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company...
Company announcement – No. 29 / 2022 Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities Copenhagen, DK and...
Company announcement – No. 28 / 2022 Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022 Copenhagen, DK and Boston, MA, 10 June...